NAMA
TXG icon

Nikko Asset Management Americas’s 10x Genomics TXG Stock Holding History

Nikko Asset Management Americas’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161M Sell
4,192,517
-911,661
-18% -$23.9M 2.07% 14
2026
Q1 		$108M Sell
5,104,178
-381,975
-7% -$7.64M 1.53% 18
2025
Q4 		$89.4M Buy
5,486,153
+109,270
+2% +$1.65M 1.03% 31
2025
Q3 		$62.9M Sell
5,376,883
-632,770
-11% -$8.25M 0.61% 43
2025
Q2 		$69.5M Buy
6,009,653
+646,997
+12% +$5.9M 0.69% 38
2025
Q1 		$46.8M Sell
5,362,656
-350,828
-6% -$4.42M 0.6% 42
2024
Q4 		$82M Sell
5,713,484
-659,728
-10% -$10.4M 0.89% 32
2024
Q3 		$144M Buy
6,373,212
+224,960
+4% +$4.65M 1.63% 18
2024
Q2 		$119M Buy
6,148,252
+2,526,474
+70% +$66.2M 1.38% 23
2024
Q1 		$136M Buy
3,621,778
+1,338,248
+59% +$58.8M 1.35% 21
2023
Q4 		$128M Buy
2,283,530
+565,059
+33% +$24.6M 1.23% 23
2023
Q3 		$70.9M Sell
1,718,471
-47,163
-3% -$2.45M 0.85% 28
2023
Q2 		$98.6M Sell
1,765,634
-255,435
-13% -$13.8M 1.04% 25
2023
Q1 		$110M Sell
2,021,069
-156,919
-7% -$7.33M 1.26% 22
2022
Q4 		$79.4M Sell
2,177,988
-29,270
-1% -$957K 1.14% 23
2022
Q3 		$61.1M Buy
2,207,258
+793,419
+56% +$30.2M 0.78% 28
2022
Q2 		$56.6M Sell
1,413,839
-17,934
-1% -$930K 0.7% 33
2022
Q1 		$109M Buy
1,431,773
+183,813
+15% +$16.1M 0.8% 28
2021
Q4 		$166M Sell
1,247,960
-85,584
-6% -$13.1M 0.87% 30
2021
Q3 		$192M Sell
1,333,544
-208,044
-13% -$35.7M 0.82% 34
2021
Q2 		$299M Buy
1,541,588
+498,675
+48% +$90.2M 1.17% 27
2021
Q1 		$189M Buy
1,042,913
+924,534
+781% +$160M 0.92% 35
2020
Q4 		$16.8M Buy
118,379
+16,111
+16% +$2.34M 0.1% 108
2020
Q3 		$12.2M Sell
102,268
-103,945
-50% -$10.9M 0.11% 103
2020
Q2 		$17.8M Buy
+206,213
New +$16.1M 0.23% 65

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nikko Asset Management Americas's TXG Position: Q2 2026 in Review

Nikko Asset Management Americas reduced its 10x Genomics (TXG) stake by 18% in Q2 2026, selling an estimated $23.9M and leaving 4,192,517 shares worth $161M. The position accounts for 2.07% of the portfolio, ranked #14.

Nikko Asset Management Americas first reported a position in TXG in Q2 2020 and has held it in 25 quarters since. The position peaked at $299M in Q2 2021. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Nikko Asset Management Americas held 4,192,517 shares of 10x Genomics worth $161M as of Q2 2026.
  • Nikko Asset Management Americas sold 911,661 10x Genomics shares in Q2 2026, an estimated $23.9M.
  • 10x Genomics made up 2.07% of Nikko Asset Management Americas's portfolio in Q2 2026, its #14 holding.
  • Nikko Asset Management Americas first reported a position in 10x Genomics in Q2 2020 and has held it in 25 quarters since.
  • Nikko Asset Management Americas's 10x Genomics position peaked at $299M in Q2 2021.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.